PMS Registry
Company Name
Boehringer Ingelheim Taiwan
Protocol Number
Title of Study
Patients’ Assessment of Satisfaction for Stroke Prevention in Atrial FibrillationImpact of Conventional Oral Anticoagulant (OAC) Compared with Novel Oral Anticoagulant (NOAC)
Primary Objective
Objective 1
To describe the treatment perception from patients with non-valvular atrial fibrillation (NVAF) receiving Pradaxa® or VKA for stroke prevention by using the self-estimation questionnaire of PACT-Q during a 6-month study period.
Objective 2
To investigate the patient’s characteristics.
Number of Sites
Period of Study
From:2017Jun 01 to:2018 Dec 31
Number of Patients
IRB Approval Date
中國附醫 08-May-2017
Publication Plan / Date
20 December 2018